Education
About Us
Working with TipRanks
Follow Us
Acurx Pharmaceuticals Llc (ACXP)
:ACXP
Top Page
Acurx Pharmaceuticals
(NASDAQ:ACXP)
37Underperform
Positive Factors
Clinical Trials
Ibezapolstat demonstrated a high clinical cure rate of 96% in Phase 2 studies, indicating strong efficacy for treating C. difficile Infection.
Regulatory Approval
Alignment with a second major regulatory agency was a key milestone, confirming that the clinical, non-clinical, and CMC data package sufficiently supports ibezapolstat's entry into a Phase 3 program for treating C. difficile Infection in the EU.
Negative Factors
Investment Risks
Risks to the investment thesis and target price include failure or equivocal data in the Phase 3 trials of ibezapolstat.
Acurx Pharmaceuticals (ACXP) vs. S&P 500 (SPY)
Market Cap
$10.01M
Dividend YieldN/A
Average Volume (3M)352.15K
Price to Earnings (P/E)―
Beta (1Y)-0.18
Revenue GrowthN/A
EPS Growth-4.10%
CountryUS
Employees4
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.09
Shares Outstanding21,762,510
10 Day Avg. Volume301,323
30 Day Avg. Volume352,147
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$12.00Price Target Upside2508.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Acurx Pharmaceuticals Business Overview & Revenue Model
Company DescriptionAcurx Pharmaceuticals (ACXP) is a clinical stage biopharmaceutical company focused on developing new antibiotics for infections caused by bacteria listed as priority pathogens. The company seeks to address the growing issue of antibiotic resistance with its innovative treatment options. Its lead product candidate, ibezapolstat, is designed to treat Clostridioides difficile infections (CDI), a serious and potentially life-threatening condition.
How the Company Makes MoneyAcurx Pharmaceuticals makes money primarily through the development and commercialization of its antibiotic products. The company aims to generate revenue by obtaining regulatory approval for its drug candidates and subsequently bringing them to market. Revenue streams include sales of approved drugs, potential licensing agreements with other pharmaceutical companies, and partnerships for further development and distribution. Additionally, the company may receive milestone payments and royalties from these collaborations, contributing to its earnings.
Acurx Pharmaceuticals Financial Statement Overview
Summary
Acurx Pharmaceuticals faces significant financial challenges with no revenue generation and sustained losses impacting its financial health. Despite a debt-free balance sheet, declining equity and reliance on financing for cash flow highlight underlying risks. Strategic improvements are essential for long-term viability.Income Statement
The company has reported no revenue over the periods analyzed, reflecting challenges in commercializing its products. Negative EBIT and net income indicate continued operational and financial challenges. The lack of revenue growth and persistent losses are significant weaknesses.10
Very Negative
Balance Sheet
Acurx Pharmaceuticals maintains a debt-free structure, which is a strength, but its equity has been declining due to ongoing losses. The equity ratio has decreased, indicating a reduced buffer for absorbing losses. Although cash reserves are diminishing, they still cover liabilities, reflecting a moderate financial position.40
Negative
Cash Flow
The company has negative operating and free cash flows, indicating a reliance on external financing. While financing inflows have supported operations, the inability to generate positive cash flow from operations poses a risk to long-term sustainability.20
Very Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | EBIT |
| -16.44M | -14.58M | -12.09M | -12.88M | -4.60M | -5.93M | EBITDA |
| -7.94M | 0.00 | -12.09M | 0.00 | -4.60M | -5.93M | Net Income Common Stockholders |
| -2.84B | -14.58M | -12.09M | -12.68M | -4.60M | -5.93M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 2.48M | 7.47M | 9.11M | 12.96M | 3.18M | 2.48M | Total Assets |
| 0.00 | 7.71M | 9.38M | 13.25M | 3.22M | 2.53M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 66.50K | 0.00 | Net Debt |
| 2.48M | -7.47M | -9.11M | -12.96M | -3.11M | -2.48M | Total Liabilities |
| 0.00 | 3.04M | 2.06M | 843.91K | 522.43K | 1.71M | Stockholders Equity |
| 819.85K | 4.67M | 7.32M | 12.41M | 2.70M | 819.85K |
| Cash Flow | Free Cash Flow | ||||
| -12.33M | -9.80M | -7.54M | -5.01M | -3.35M | -3.99M | Operating Cash Flow |
| -12.33M | -9.80M | -7.54M | -5.01M | -3.35M | -3.99M | Investing Cash Flow |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Financing Cash Flow |
| 6.43B | 8.16M | 3.70M | 14.80M | 4.04M | 4.46M |
Acurx Pharmaceuticals Technical Analysis
Negative
0.46
Price Trends
0.75
Negative
1.08
Negative
1.63
Negative
Market Momentum
-0.08
Positive
30.18
Neutral
8.32
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACXP, the sentiment is Negative. The current price of 0.46 is below the 20-day moving average (MA) of 0.66, below the 50-day MA of 0.75, and below the 200-day MA of 1.63, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 30.18 is Neutral, neither overbought nor oversold. The STOCH value of 8.32 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACXP.
Acurx Pharmaceuticals Risk Analysis
Acurx Pharmaceuticals disclosed 54 risk factors in its most recent earnings report. Acurx Pharmaceuticals reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Acurx Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $348.15M | 20.06 | 531.78% | ― | 53.38% | ― | |
56 Neutral | $26.99M | ― | -62.70% | ― | 47.05% | 40.66% | |
51 Neutral | $318.22M | ― | -136.87% | ― | ― | 21.19% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
39 Underperform | $93.19M | ― | -31.30% | ― | ― | 9.11% | |
37 Underperform | $10.01M | ― | -498.16% | ― | ― | -4.10% |
* Healthcare Sector Average
Performance Comparison
ACXP
Acurx Pharmaceuticals
0.46
-2.25
-83.03%
RIGL
Rigel
20.43
7.13
53.61%
VSTM
Verastem
7.53
-2.97
-28.29%
ATOS
Atossa Therapeutics
0.72
-0.48
-40.00%
PULM
Pulmatrix
8.11
6.37
366.09%
Acurx Pharmaceuticals Earnings Call Summary
Earnings Call Date: Nov 13, 2024 | % Change Since: -75.14% | Next Earnings Date: Mar 18, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant progress in clinical trials and regulatory readiness, which are promising for future developments. However, financial challenges and the need for funding to proceed with Phase III trials pose risks.Highlights
Phase II Clinical Trial Success
The ibezapolstat Phase II clinical trial showed promising results in treating C. diff infections, with no recurrence in patients followed for three months post-treatment.
New Patent Granted
Acurx received a patent for ibezapolstat, which reduces recurrence of C. difficile infection and improves gut microbiome health. This patent is valid until June 2042.
FDA Phase III Readiness
Achieved CMC readiness for Phase III trials, with FDA agreement on clinical plans, indicating regulatory progress.
Participation in Global Conferences
Acurx presented at multiple international conferences, highlighting progress and the potential of their antibiotic programs.
Potential Economic Impact
Ibezapolstat could reduce the U.S. annual cost burden for C. difficile infection, currently at $5 billion, by addressing recurrence.
Lowlights
Financial Losses
Reported a net loss of $2.8 million for Q3 2024, though slightly improved from a $3.1 million loss in Q3 2023.
Cash Reduction
Cash reserves decreased to $5.8 million from $7.5 million at the end of 2023, indicating financial pressure.
Increased R&D Expenses
Research and development expenses rose to $4.6 million for the first nine months of 2024, up from $4.1 million in the same period of 2023.
Uncertain Phase III Funding
Funding for Phase III trials remains uncertain, with ongoing discussions for partnerships and government support.
Company Guidance
During the ACXP earnings call for Q3 2024, the executive team provided guidance on several fronts. They highlighted the company's cash position at $5.8 million as of September 30, 2024, down from $7.5 million at the end of 2023, while raising $1.6 million through an ATM financing program in the third quarter. Research and development expenses were $1.2 million, a slight decrease from the previous year's $1.3 million, primarily due to a reduction in consulting fees. General and administrative expenses fell to $1.6 million from $1.8 million year-over-year, despite an increase in professional fees and compensation costs. The net loss for the quarter was $2.8 million, or $0.17 per diluted share, an improvement from a $3.1 million loss in the same period last year. The company reported a net loss of $11.3 million for the nine months ended September 30, 2024, compared to a $9.5 million loss in the prior year, driven by increased manufacturing-related costs. Management outlined plans for Phase III trials of ibezapolstat, aiming to raise funds either through partnerships or government programs to proceed with these pivotal studies.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.